Notícias e Atividades da Jasper Therapeutics

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Jasper Therapeutics

• Jeet Mahal, President and Chief Executive Officer and Director
• Judith Shizuru, Director
• Thomas Wiggans, Executive Chairman of the Board

Recentes movimentos de executivos em Jasper Therapeutics

• Chris Nolet, Director, deixou a Companhia  (Notícia publicada em 22 de maio de 2026).
• Ronald Martell, Chief Executive Officer and Director, deixou a Companhia  (Notícia publicada em 8 de janeiro de 2026).
• Jeet Mahal antes Chief Operating Officer, foi promovido a President and Chief Executive Officer and Director  (Notícia publicada em 8 de janeiro de 2026).

Criar um alerta
para seguir os movimentos de executivos da Jasper Therapeutics.

Jasper Therapeutics possui 2.405 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e BioNTech (Alemanha).

Popular M&A news in Biotecnologia

• IMU Biosciences acaba de anunciar uma arrecadação de fundos de 53 milhões de dólares. (publicado em 3 de junho de 2026).
• NewLimit acaba de anunciar uma arrecadação de fundos de 435 milhões de dólares. (publicado em 3 de junho de 2026).
• Rallybio and Avenzo Therapeutics have announced they will merge  (publicado em 1 de junho de 2026)..

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Valerie Hanote - Non-Executive Director da Eurofins

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Jasper Therapeutics

• News Releases | Jasper Therapeutics, Inc
• News Releases | Jasper Therapeutics, Inc
• Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene Therapy for the Treatment of Sickle Cell Disease
• Jasper Therapeutics Announces Orphan Drug and Rare Pediatric Disease Designations for JSP191 for Conditioning Treatment Prior to Stem Cell Transplant | Business Wire
• Jasper Therapeutics to Host Webcast to Review Updated 90-day Data from Phase 1 Clinical Trial of JSP191 That is Being Presented at 2021 ASCO Virtual Annual Meeting | Business Wire
• Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous Disease | Business Wire
• Jasper Therapeutics Announces Updated 90-day Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Older Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Bus
• Jasper Therapeutics and Amplitude Healthcare Acquisition Corporation Announce Merger to Create a Publicly Listed Leading Biotechnology Company in Hematopoietic Stem Cell Transplantation | Business Wire
• Jasper Therapeutics Announces Launch of New Clinical Trial with National Heart, Lung, and Blood Institute to Evaluate JSP191 in Sickle Cell Disease | Business Wire
• Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted Stem Cell Conditioning Agent in Patients with Myelodysplastic Syndromes or Acute Myeloid Leukemia Undergoing Hematopoietic Cell Transplantation | Business Wire
• View more press releases Close

Redes sociais sobre Jasper Therapeutics

• Jasper Therapeutics na Wikipedia, Google News e Yahoo Finance
• Jasper Therapeutics na LinkedIn, X (Twitter) e YouTube